Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes

Recruiting now · Not applicable

Conditions studied: Glioma

In brief

The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.

Key facts

Study ID

NCT06116903

Run by

University Hospital, Limoges

People needed

60

Starts

2024-04-11

Expected to finish

2025-12-15

Last updated by the study team

2024-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject of both sexes at least 18 years of age with glioblastoma.
• Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol)
• Patient affiliated to French social security

You may not qualify if…

• Patient included in another research protocol using an experimental molecule.
• Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol
• Patient under legal protection, guardianship or curatorship
• Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.

Where it is running

• CHU de Limoges — Limoges, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.